AAAAAA

   
Results: 1-8 |
Results: 8
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study
Authors: Mocroft, A Phillips, AN Miller, V Gatell, J van Lunzen, J Parkin, JM Weber, R Roge, B Lazzarin, A Lundgren, JD
Citation: A. Mocroft et al., The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study, AIDS, 15(2), 2001, pp. 201-209
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
Authors: Reiss, P Vella, S Cooper, D Lange, J Gartland, M Gerstoft, J Goebel, F Larder, B Clumeck, N Gatell, J Gazzard, B Rozenbaum, W Rae, S O'Shaughnessy, MV Robinson, P Harrigan, PR Raboud, J Alexander, CS Maguire, M Montaner, JS
Citation: P. Reiss et al., Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit, AIDS, 14(10), 2000, pp. 1383-1388
A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival
Authors: Mocroft, A Madge, S Johnson, AM Lazzarin, A Clumeck, N Goebel, FD Viard, JP Gatell, J Blaxhult, A Lundgren, JD
Citation: A. Mocroft et al., A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival, J ACQ IMM D, 22(4), 1999, pp. 369-378
Coming therapies: amprenavir
Authors: Gatell, J
Citation: J. Gatell, Coming therapies: amprenavir, INT J CL PR, 1999, pp. 42-44
AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients
Authors: Gatell, J Lange, J Gartland, M
Citation: J. Gatell et al., AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients, ANTIVIR TH, 4(2), 1999, pp. 79-86
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence
Authors: Abrams, D Allan, D Antunes, F Breckenridge, A Bruun, J Cameron, W Carbon, C Chalmers, I Chang, H Chodakewitz, J Clendenin, N Clumeck, N Collier, A Collins, G Cooper, E Cooper, D Danner, S D'Aquila, R DeGruttola, V DeMasi, R Dee, L Deyton, L Dixon, D Farthing, C Feinberg, J Fischl, M Flepp, M Gartland, M Gatell, J Gazzard, B Goebel, F Gotzsche, P Gringeri, A Hall, D Hamilton, J Hammer, S Hartigan, P Heath-Chiozzi, M Henry, K Hill, A Hirschel, B Ioannidis, J Kahn, J Katlama, C Katzenstein, D Killen, J King, E de Loes, SK Kravcik, S Lange, J Leavitt, R Leonard, J Maeland, A Mannucci, P Mathiesen, L McDade, H Meibohn, A Melander, H Merigan, T Mulder, J Myers, M Neaton, J Nessling, M Perrin, L Pettinelli, C Phair, J Phillips, A Pinching, A Poppa, A Power, L Reiss, P Richman, D Rooney, J Rousseau, F Rutherford, G Salgo, M Sandstrom, E Saravolatz, L Savidge, G Schnittman, S Schooley, R Seligmann, M Simberkoff, M Skowron, G Slade, P Smith, D Smith, RP Soriano, V Stanley, K Stingl, G Stoffels, P Struthers, L Tierney, C Thompson, M Van der Broeck, R Van Leeuven, R Van Weverling, G Veenstra, J Vella, S Volberding, P Weber, J Winslow, D Yeni, P Yeo, J Dormont, J Sande, M Weller, I Babiker, A Collins, R Darbyshire, J Duncan, W Foulkes, M Hughes, M Peto, R Peto, T Walker, S
Citation: D. Abrams et al., Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence, LANCET, 353(9169), 1999, pp. 2014-2025
High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors
Authors: Martinez, E Gatell, J Moran, Y Aznar, E Buira, E Guelar, A Mallolas, J Soriano, E
Citation: E. Martinez et al., High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors, CLIN INF D, 27(6), 1998, pp. 1510-1513
Risultati: 1-8 |